SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John S. Baker who wrote (370)8/15/1998 10:05:00 AM
From: muddphudd  Read Replies (1) of 586
 
Follow up:

"This is a good link talking about Arava. abcnews.com It looks like it has problems. 70% of the people who have RA are women and this drug causes birth defects. Granted most of the women who get RA are probably past the child bearing years but it still makes you wonder. It also causes liver damage like most of the other so called RA cures. It doesn't cure crippling RA, which is the target market for the Prosorba column. I don't see it as a big threat to CYPB. Just another drug that helps some people some of the time but causes more problems latter. "

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News